Thus, these studies demonstrated that PD-L1 was often expressed on circulating metastatic cells in triple-negative and HER2-positive BC patients, in which patients with a high percentage of PD-L1-positive CTCs had to be identified as potential candidates for anti-PD-L1 therapy. This evidence concerns the gene ERBB2 and breast cancer.